FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Everpure: Strong Q1 Results, But Presence Of Pull-ins Questions Sustainability

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

Everpure reported Q1 FY 27 results above expectations with revenue of $1.05B (+35% Y/Y) vs consensus ~$1.00B and non-GAAP EPS of $0.47 (+62% Y/Y) vs consensus $0.40, accelerating from Q4's 20% growth pace. Non-GAAP operating margin expanded 450 bps Y/Y to 15.1%, while product revenue grew 55% Y/Y and subscription ARR reached $2B (+19% Y/Y). We view the results as concerning given management's estimate that pull-ins and price increases drove roughly 1/3 of Q1's Y/Y revenue growth, with limited visibility beyond this fiscal year. FY 27 guidance beat expectations with revenue midpoint of $4.46B (+22% Y/Y), up 300 bps from prior 19% outlook, though management noted it's too early to call for further upside. We expect further demand destruction and HDD share gains at flash memory's expense throughout FY 27 and FY 28 as pricing discrepancies widen, though results are being inflated in the interim by component cost pressures and customer pull-ins.

Related Articles

Research

Research Alert: Agilent Technologies Reports Q2 Fy 26 Sales And Eps Beats

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Agilent beat Q2 expectations with revenue of $1.83B rising 10% Y/Y (+6.3% core), topping the $1.80B consensus, while adjusted EPS of $1.49 grew 14% Y/Y, beating the $1.41 forecast. Operating leverage was notable with adjusted operating margin expanding 130 bps Y/Y to 26.4%, driven by broad-based business growth across Americas (+11%) and Europe (+8%). We view the strong performance positively, supported by ongoing instrument replacement cycles and strength in Agilent's cancer diagnostics portfolio, with Life Sciences and Diagnostics sales rising 12% Y/Y. Management raised FY 26 guidance across all key metrics, increasing revenue guidance by 30 bps at the midpoint to $7.39-7.49B (up 6.3-7.8% reported, 4.5-6.0% core) and non-GAAP EPS guidance by $0.08 to $6.00-6.10. We expect continued momentum from pharma end markets (+6% core growth) and Applied Markets (+14% revenue growth), though academic/government weakness persists with core sales down 5% Y/Y on uncertain NIH funding policy.

$A
Research

Research Alert: CFRA Reiterates Buy Opinion On Shares Of National Bank Of Canada

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After digesting Q2 results, we raise our 12-month target price by CAD15 to CAD265, which is 18.6x our FY 27 (Oct.) EPS view of CAD14.21, a premium to its five-year forward P/E of 10.9x, given expected efficiency gains and improving revenue diversity. We increase our FY 26 EPS view to CAD12.90 from CAD12.65 and our FY 27 EPS view to CAD14.21 from CAD13.97. NA is one of our top bank picks in Canada, as the bank consistently outgrows its peers. This growth is also driving efficiency improvements, with adjusted ROE averaging a strong 16.7% in 1H FY 26. Given the bank's solid performance and well-controlled expense growth, we expect full-year FY 26 ROE to approach 17%, exceeding management's 16% target. Despite macroeconomic uncertainty and renewed inflation concerns, NA raised its dividend by 6% to CAD1.32 per share. While 6% growth is still above peers, this increase is relatively conservative in our view, given our expectation for double-digit earnings growth in both FY 26 and FY 27.

$NA
Research

Research Alert: Snps Q2: Modest Fy 26 Guidance Raise And Eda Deceleration (ex-ansys)

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:SNPS posted Q2 FY26 sales of $2.28B (+42% Y/Y), slightly ahead of consensus ($2.25B), with non-GAAP EPS of $3.35 exceeding expectations of $3.16. Design Automation sales grew 62% driven by Ansys acquisition (29% of Q2 sales), while ex-Ansys growth decelerated to 9% from 12% in Q1, and Design IP declined 6% for the second consecutive quarter reflecting Intel process delays. We view the Ansys integration as progressing well with accelerating cost synergies and expect the $2.96B FY26 contribution to drive meaningful revenue acceleration. Management lifted FY26 revenue guidance to $9.665B from $9.61B and EPS to $14.76 from $14.42, supported by synergies and margin expansion. We expect continued Design IP margin pressure near-term as SNPS adjusts its portfolio, though Design Automation margins improved 240 bps Y/Y to 43.3%. The China business (11% of sales) remains stable, and we believe the combined entity positions SNPS well for AI-driven design complexity growth.

$SNPS